Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Trading Update

19 Jan 2010 07:00

RNS Number : 7435F
Cello Group plc
19 January 2010
 



19 January 2010

  

Cello Group plc

Pre-Close trading update - year ended 31 December 2009

Cello Group plc (AIM: CLL, 'the Group'),  the leading independent market research and consulting group, today publishes the following pre-close trading update for the year ended 31 December 2009 Since the announcement of the Group's interim results published in early September, there has been a marked pick up in its market research activity from a wide range of domestic and international clients, in addition to continued strength in the core pharmaceutical operation. However, this has been offset by a challenging period for aspects of the Tangible division of the Group, most notably in financial services and certain charity related work where the traditional seasonal pick up in client activity was not as robust as anticipated. The Tangible operations based in Scotland have had a strong year. Total Group revenue is expected to be in the region of £60.0m.

As highlighted in the interim results, the Group's cost reduction programme continued in the second halfThe total cost base in 2009 is expected to be between £4.0m and £4.5m lower than 2008 as a result of reduced headcount and property consolidation, which will give rise to an exceptional cost of around £1.9m.

As a result, the Board anticipates that the Group's headline profit before tax will be approximately £5.0m.The Group's strong cash conversion continued in the second half of 2009, as a result of which the Board expects to report year end net debt of between £11.5m and £12.0m, down from £14.8m on 30 June 2009.Whilst the Board remains realistically cautious about the current outlook and it is too early to give detailed guidance for 2010, the Group is seeing refreshed levels of spend across major research clients, with pharmaceutical and health related research showing particular strengthThe pipeline of research work is significantly stronger than at the same time last year. Therefore, following the substantial reduction in low margin and non-profitable activities, the Group is in a strong position to push for organic growth in 2010. The Group expects to announce its preliminary results for the year ended 31 December 2009 on Wednesday 17 March 2010. 

 

Enquiries:

 

Cello Group 

 020 7812 8460

Mark ScottChief Executive

Mark Bentley, Finance Director

 

Altium 

 020 7484 4040

Ben Thorne

Paul Chamberlain

 

College Hill

 020 7457 2020

Adrian Duffield/Rozi Morris

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEAXFPFELEEFF
Date   Source Headline
20th Jul 202012:21 pmRNSForm 8.3 - Cello Health Plc
17th Jul 20209:14 amRNSForm 8.3 - Cello Health PLC
16th Jul 20205:00 pmRNSForm 8.3 - Cello Health plc
16th Jul 20208:48 amRNSForm 8.3 - Cello Health PLC
16th Jul 20207:00 amRNSForm 8.3 - Cello Health Plc
15th Jul 20203:00 pmRNSUpdate re: antitrust clearances
15th Jul 20201:44 pmRNSForm 8.3 - Cello Health Plc
15th Jul 20201:21 pmRNSHolding(s) in Company
15th Jul 20208:55 amRNSForm 8.3 - Cello Health PLC
14th Jul 20201:33 pmRNSForm 8.3 - Cello Health plc
14th Jul 20208:51 amRNSForm 8.3 - Cello Health PLC
14th Jul 20208:04 amRNSHolding(s) in Company
14th Jul 20207:01 amRNSHolding(s) in Company
13th Jul 20203:15 pmBUSForm 8.3 - Cello Health plc
13th Jul 202010:51 amBUSForm 8.3 - CELLO HEALTH PLC
13th Jul 20208:18 amRNSForm 8.3 - Cello Health PLC
13th Jul 20207:00 amRNSHolding(s) in Company
13th Jul 20207:00 amRNSPublication of Scheme Document
10th Jul 20203:20 pmRNSForm 8.3 - Cello Health Plc
10th Jul 20203:17 pmRNSForm 8.3 - Cello Health PLC
10th Jul 20203:10 pmPRNForm 8.3 - Cello Health Plc
10th Jul 20201:34 pmBUSForm 8.3 - CELLO HEALTH PLC
10th Jul 202010:11 amRNSHolding(s) in Company
10th Jul 20209:41 amRNSForm 8.3 - Cello Health Plc
10th Jul 20208:51 amRNSForm 8.3 - Cello Health PLC
9th Jul 20206:20 pmRNSUpdate on letters of intent
9th Jul 20205:38 pmRNSHolding(s) in Company
9th Jul 20203:20 pmRNSForm 8.3 - Cello Health
9th Jul 20203:17 pmRNSForm 8.3 - CELLO HEALTH PLC
9th Jul 20203:08 pmRNSForm 8.3 - Cello Health PLC
9th Jul 20203:00 pmBUSForm 8.3 - Cello Health Plc
9th Jul 202012:33 pmRNSHolding(s) in Company
9th Jul 202011:31 amRNSForm 8.3 - Cello Health Plc
9th Jul 20209:20 amRNSForm 8.3 - Cello Health plc
9th Jul 20209:10 amRNSForm 8.3 - Cello Health PLC
9th Jul 20207:00 amRNSUpdate on irrevocable undertakings
8th Jul 20203:56 pmPRNForm 8.3 - Cello Health Plc
8th Jul 20203:00 pmBUSForm 8.3 - Cello Health Plc
8th Jul 20202:00 pmRNSForm 8.3 - Cello Health Plc
8th Jul 202012:45 pmRNSForm 8.3 - Cello Health plc
8th Jul 202010:35 amRNSForm 8.3 - Cello Health PLC
8th Jul 20209:55 amRNSForm 8.3 - Cello Health plc
8th Jul 20208:54 amPRNForm 8.3 - Cello Health plc
8th Jul 20207:00 amRNSUpdate on irrevocable undertakings
8th Jul 20207:00 amRNSForm 8.3 - Cello Health PLC
7th Jul 20203:20 pmRNSForm 8.3 - Cello Health
7th Jul 20203:19 pmRNSForm 8.3 - CELLO HEALTH PLC
7th Jul 20203:00 pmBUSForm 8.3 - Cello Health Plc
7th Jul 202010:08 amRNSCELLO HEALTH PLC
7th Jul 20209:16 amPRNForm 8.3 - Cello Health Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.